PCSK9 Forum
Click here to invite colleagues
to join the Forum for FREE
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
Cardiovascular disease prevention in 2015
CVD prevention in the last 12 months
A momentous year in cardiology

Last year saw exciting developments in the prevention of cardiovascular (CV) disease.

This was the year that PCSK9 inhibitors became available for clinical use in the USA, Europe and elsewhere. From data presented and published in 2015 the ability of these innovative agents to reduce LDL-cholesterol to new levels was clearly established. And, for the first time, studies pointed to consequent reductions in CV outcomes, setting the scene for the year to come.

In a review of the year, Professor John Chapman and co-authors discuss these and other important events.

Read full report »

Forward to colleagues »

Chapman MJ, Blankenberg S, Landmesser U. The year in cardiology 2015: prevention. Eur Heart J. 2016 Jan 3. pii: ehv721. [Epub ahead of print]
Editors choice

Forum editors select some of the key developments in the last 12 months:

1   The promise of PCSK9 inhibition may deliver in reducing cardiovascular outcomes.

2 & 3   Meta-analyses provide further evidence of cardiovascular benefit and reassurance on safety.

4   Reassurance on effects of PCSK9 inhibition on vitamin E and steroid hormone levels.

5 & 6   Familial hypercholesterolaemia (FH, inherited high cholesterol) has finally received much warranted attention.

7   Largest dataset of heterozygous FH patients treated with a PCSK9 inhibitor (ODYSSEY programme).

8   Norwegian registry study clearly shows that even in the post-statin era, FH is undertreated.

9   IMPROVE-IT: a landmark study

10   Concluding the Top 10 parade is the timely up to date PCSK9 review from the Editors, free to download from PCSK9 Forum.

Read full report »
Click here to invite colleagues to join FREE
Questions & Answers

Why are new treatments needed?

Millions of people who suffer with hypercholesterolaemia remain at a high risk of premature death, despite current treatment.

Read the full answer and other questions on the PCSK9 Forum »
Free e-book
Understanding PCSK9 inhibition
For healthcare professionals

Prepared by independent experts from PCSK9 Education and Research Forum.

Register and read online »    Download now »
PCSK9 Inhibition Handbook
Like us on Facebook
For the latest updates, PCSK9 news and analysis.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Educational Partners
and Supporters
Amgen Lilly The Medicines Company pFizer Sanofi
Copyright PCSK9 Forum 2016. Please click here to unsubscribe from future mailings.